{
    "clinical_study": {
        "@rank": "15021", 
        "arm_group": [
            {
                "arm_group_label": "MRT-Active", 
                "arm_group_type": "Experimental", 
                "description": "Magnetic Field, modulated as per EEG analysis, is active for 6 seconds every minute for 30 minutes per day, 5 days per week x 5 weeks."
            }, 
            {
                "arm_group_label": "MRT-SHAM", 
                "arm_group_type": "Sham Comparator", 
                "description": "Magnetic field is not active, but a sham coil is used,  for 6 seconds every minute for 30 minutes per day, 5 days per week x 5 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to show that a magnetic field applied to the front part of the\n      brain of children suffering from Autism Spectrum Disorder(ASD) can improve function and\n      ameliorate symptoms."
        }, 
        "brief_title": "A Trial To Evaluate The Efficacy of Magnetic Resonant Therapy in Autism", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Autism Spectrum Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Autistic Disorder", 
                "Child Development Disorders, Pervasive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Primary diagnosis of Autism Spectrum Disorder by DSM-IV-TR rendered by the\n             examination and sufficient CARS-2 score to qualify as autism.\n\n          -  CARS score between 36 and 47 inclusively\n\n          -  Age between 4 and 12 years (at day of informed consent)\n\n          -  Child must suffer disrupted sleep patterns defined as a minimum of 3 nights per week\n             of delayed onset of sleep or night-time awakenings. If these are medicated with mild\n             sedatives or melatonin and corrected, the requirement for medication or melatonin\n             will qualify as evidence of a sleep disorder.\n\n        Exclusion Criteria:\n\n          -  Diagnosis of Asperger's Disorder, Pervasive Developmental Disorder Not Otherwise\n             specified\n\n          -  History of clinically significant traumatic brain injury\n\n          -  Any condition associated with increased intracranial pressure\n\n          -  Cerebral Aneurysm\n\n          -  Down's Syndrome or other chromosomal abnormality\n\n          -  EEG abnormalities that indicate seizure risk\n\n          -  Intracranial implant\n\n          -  Unstable medical condition not otherwise specified\n\n          -  Clinically significant organic disease unrelated to autism"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Years", 
            "minimum_age": "4 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01985308", 
            "org_study_id": "MRT-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "MRT-Active", 
                "intervention_name": "MRT-Active", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "MRT-SHAM", 
                "intervention_name": "MRT-SHAM", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Newport Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92660"
                    }, 
                    "name": "Brain Treatment Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buford", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30518"
                    }, 
                    "name": "Brain Treatment Center of Atlanta"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Double-Blind Sham-Controlled Trial To Evaluate The Treatment Efficacy of Magnetic Resonant Therapy in Autistic Disorder", 
        "overall_official": {
            "last_name": "Jeff Bradstreet, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Difference in CARS score between start and end of double-blind portion of the study", 
            "measure": "Childhood Autism Rating Scale (CARS)", 
            "safety_issue": "No", 
            "time_frame": "5 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01985308"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Newport Brain Research Laboratory", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Newport Brain Research Laboratory", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}